Risky Business: Prophylaxis and Treatment of Cytomegalovirus in the Transplantation Setting

1.25 CME
75 MINS
$0 FEE
SAVE
J579

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by educational grants from Merck & Co., Inc. and Shire.  


Target Audience

The intended audience for this activity is infectious disease specialists, hematologists, oncologists, and other health care professionals involved in the treatment of patients with cytomegalovirus (CMV).


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Summarize the current use of antiviral regimens to prevent CMV disease in transplant recipients. 
  • Assess the latest clinical evidence regarding newer antivirals and vaccines for use as prophylactic or preemptive anti-CMV therapy in transplant recipients.
  • Compare evidence-based guidelines and recent clinical trial data on the safety and efficacy of prophylaxis and treatment of CMV in the transplantation setting.
  • Evaluate novel therapeutics and vaccines in development for their ability to control the excess mortality and health care resource utilization associated with CMV.

Activity Chair

Genovefa A. Papanicolaou, MD, FIDSA 
Attending Physician, Director of Clinical Trials, Infectious Disease Service 
Memorial Sloan Kettering Cancer Center 
Professor of Medicine, Weill Cornell Medical College 
New York, NY


Faculty

Michael G. Ison, MD, MS, FIDSA, FAST 
Professor, Divisions of Infectious Diseases and Organ Transplantation 
Northwestern University Feinberg School of Medicine 
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL

Francisco M. Marty, MD, FIDSA 
Brigham and Women's Hospital, Dana-Farber Cancer Institute 
Associate Professor of Medicine, Harvard Medical School
Boston, MA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release December 13, 2018 to December 12, 2019.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.


Activity Chair and Faculty report the following relationships

Michael G. Ison, MD, MS, FIDSA, FAST 
Royalty: UpToDate
Consulting Fee: Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Toyama/MediVector, Vir Biotechnology
Contracted Research: Beckman Coulter, Cepheid, Chimerix, Emergent BioScience, Gilead, Janssen, Shire
Data Safety & Monitoring Board: GlaxoSmithKline, Shionogi

Francisco M. Marty, MD, FIDSA 
Consulting Fee: GlaxoSmithKline, Merck

Genovefa A. Papanicolaou, MD, FIDSA 
Consulting Fee: Astellas, Chimerix, Merck
Contracted Research: Astellas, Chimerix, Merck, Shire 


Reviewer reports the following relationship(s)

Ronald A. Codario MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose.


Vindico Medical Education staff report the following relationship(s)

No relevant financial relationship to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com